Brief: Aileron Therapeutics Announces Termination Of Phase 1B Breast Cancer Chemoprotection Trial

Rein Therapeutics

21/02/2023 13:48

Feb 21 (Reuters) - Aileron Therapeutics Inc  ALRN.O :
    * AILERON THERAPEUTICS ANNOUNCES TERMINATION OF PHASE 1B
BREAST
CANCER CHEMOPROTECTION TRIAL AND EXPLORATION OF STRATEGIC
ALTERNATIVES
    * AILERON THERAPEUTICS INC: AILERON HAS DECIDED TO TERMINATE
PHASE
1B BREAST CANCER TRIAL AND FURTHER DEVELOPMENT OF ALRN-6924
    * AILERON THERAPEUTICS INC - HAS DETERMINED TO REDUCE ITS
REMAINING WORKFORCE FROM 9 TO 3 FULL-TIME EMPLOYEES IN COMING
WEEKS
    * AILERON THERAPEUTICS INC: EXPLORING A RANGE OF STRATEGIC
ALTERNATIVES TO MAXIMIZE SHAREHOLDER VALUE
    * AILERON THERAPEUTICS INC: COMPANY HAS ENGAGED LADENBURG
THALMANN
& CO., INC. TO ACT AS A STRATEGIC ADVISOR FOR THIS PROCESS
    * AILERON THERAPEUTICS INC - AILERON ALSO ANNOUNCED THAT IT
IS
EXPLORING A RANGE OF STRATEGIC ALTERNATIVES TO MAXIMIZE
SHAREHOLDER VALUE
    * AILERON THERAPEUTICS INC - PLANS TO RETAIN REMAINING
EMPLOYEES
TO ASSIST IN EXECUTING STRATEGIC ALTERNATIVES REVIEW PROCESS
    * AILERON THERAPEUTICS INC: STRATEGIC ALTERNATIVES MAY
INCLUDE,
BUT NOT LIMITED TO, AN ACQUISITION, A MERGER, A BUSINESS
COMBINATION, A SALE OF ASSETS
    * AILERON THERAPEUTICS INC: HAS DETERMINED TO REDUCE ITS
REMAINING
WORKFORCE FROM 9 TO 3 FULL-TIME EMPLOYEES IN COMING WEEKS

Source text for Eikon:  ID:nGNX1RlK7d 
Further company coverage:  ALRN.O 
 ((Reuters.Briefs@thomsonreuters.com;))